The US Food and Drug Administration (FDA) will convene an external expert panel to discuss whether clinical trial data of Amylyx’s AMX0035 therapy in patients with multiple sclerosis amyotrophic lateral sclerosis (ALS) supports regulatory approval. This therapy has received wide interest from the ALS patient community because there are currently only two FDA-approved therapies in […]
Share
facebookShare on FacebooktwitterShare on TwitterpinterestShare on PinterestlinkedinShare on LinkedinvkShare on VkredditShare on ReddittumblrShare on TumblrviadeoShare on ViadeobufferShare on BufferpocketShare on PocketwhatsappShare on WhatsappviberShare on ViberemailShare on EmailskypeShare on SkypediggShare on DiggmyspaceShare on MyspacebloggerShare on BloggerYahooMailShare on Yahoo mailtelegramShare on TelegramMessengerShare on Facebook MessengergmailShare on GmailamazonShare on AmazonSMSShare on SMS
